DaVita HealthCare Partners Inc. (NYSE:DVA) had its price objective cut by Royal Bank Of Canada from $64.00 to $60.00 in a research report report published on Wednesday morning. They currently have a sector perform rating on the stock.

A number of other equities research analysts have also weighed in on the stock. Wolfe Research raised shares of DaVita HealthCare Partners from a market perform rating to an outperform rating in a report on Monday, October 23rd. SunTrust Banks, Inc. set a $57.00 price objective on shares of DaVita HealthCare Partners and gave the company a hold rating in a report on Sunday, October 15th. Zacks Investment Research lowered shares of DaVita HealthCare Partners from a hold rating to a sell rating in a report on Wednesday, October 11th. KeyCorp reissued a hold rating on shares of DaVita HealthCare Partners in a report on Tuesday, October 10th. Finally, J P Morgan Chase & Co lowered shares of DaVita HealthCare Partners from a neutral rating to an underweight rating in a report on Monday, October 9th. Four equities research analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the stock. DaVita HealthCare Partners currently has an average rating of Hold and an average target price of $64.00.

DaVita HealthCare Partners (NYSE DVA) traded up $0.77 during mid-day trading on Wednesday, hitting $55.11. 2,907,652 shares of the stock were exchanged, compared to its average volume of 1,587,180. The stock has a market capitalization of $10,540.00, a PE ratio of 16.85, a P/E/G ratio of 4.44 and a beta of 0.98. The company has a quick ratio of 1.38, a current ratio of 1.45 and a debt-to-equity ratio of 1.69. DaVita HealthCare Partners has a twelve month low of $52.51 and a twelve month high of $70.16.

DaVita HealthCare Partners (NYSE:DVA) last announced its quarterly earnings data on Tuesday, November 7th. The company reported $0.81 earnings per share for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.13). The company had revenue of $3.92 billion for the quarter, compared to analysts’ expectations of $3.91 billion. DaVita HealthCare Partners had a net margin of 3.40% and a return on equity of 13.19%. DaVita HealthCare Partners’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same period last year, the firm earned $0.95 earnings per share. equities research analysts expect that DaVita HealthCare Partners will post 3.54 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This news story was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/11/09/davita-healthcare-partners-inc-dva-given-new-60-00-price-target-at-royal-bank-of-canada.html.

DaVita HealthCare Partners declared that its board has initiated a share repurchase plan on Tuesday, October 10th that allows the company to buyback $1.50 billion in shares. This buyback authorization allows the company to repurchase shares of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its stock is undervalued.

A number of hedge funds and other institutional investors have recently bought and sold shares of DVA. Migdal Insurance & Financial Holdings Ltd. acquired a new position in DaVita HealthCare Partners during the third quarter valued at $154,000. Pzena Investment Management LLC lifted its position in DaVita HealthCare Partners by 2.1% during the second quarter. Pzena Investment Management LLC now owns 3,398 shares of the company’s stock valued at $220,000 after purchasing an additional 71 shares during the period. Eqis Capital Management Inc. lifted its position in DaVita HealthCare Partners by 2.2% during the second quarter. Eqis Capital Management Inc. now owns 4,600 shares of the company’s stock valued at $298,000 after purchasing an additional 100 shares during the period. Thrivent Financial For Lutherans raised its position in shares of DaVita HealthCare Partners by 4.4% in the first quarter. Thrivent Financial For Lutherans now owns 5,730 shares of the company’s stock worth $389,000 after acquiring an additional 240 shares during the period. Finally, Jensen Investment Management Inc. raised its position in shares of DaVita HealthCare Partners by 24.2% in the second quarter. Jensen Investment Management Inc. now owns 9,740 shares of the company’s stock worth $631,000 after acquiring an additional 1,900 shares during the period. Institutional investors own 82.72% of the company’s stock.

About DaVita HealthCare Partners

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Analyst Recommendations for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Stock Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related stocks with our FREE daily email newsletter.